- Citations, last 5 years
- 705
- Works, last 5 years
- 121
- h-index
- 156
- Scientists listed
- 10
- Grants since 2016
- 74
Grants received
2023–2026 · grant · SB1
Progressing PfSPZ vaccines for malaria to licensure and commercialization
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2023–2025 · research · R43
Conditional male lethal Anopheles stephensi line for the efficient manufacture of malaria vaccines
Peter F. Billingsley · Sanaria · funded by National Institutes of Health
2023–2025 · research · R43
Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2023–2025 · research · R43
Conditional male lethal Anopheles stephensi line for the efficient manufacture of malaria vaccines
Peter F. Billingsley · Sanaria · funded by National Institutes of Health
2023–2025 · research · R43
Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2023–2026 · grant · SB1
Progressing PfSPZ vaccines for malaria to licensure and commercialization
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2023–2027 · grant · SB1
Progressing PfSPZ vaccines for malaria to licensure and commercialization
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2022–2024 · cooperative agreement · U44
PfSPZ Vaccine for Prevention of Plasmodium falciparum malaria
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2022–2025 · research · R43
In vitro bioreactor production of a genetically modified late liver stage-arresting replication competent Plasmodium falciparum sporozoite vaccine
B. Kim Lee Sim · Sanaria · funded by National Institutes of Health
2022–2024 · research · R43
In vitro bioreactor production of a genetically modified late liver stage-arresting replication competent Plasmodium falciparum sporozoite vaccine
B. Kim Lee Sim · Sanaria · funded by National Institutes of Health
2022–2023 · contract · N43
Development of monoclonal antibody-mediated interventions to combat malaria
Susan Rupprecht · Sanaria · funded by National Institutes of Health
2021–2026 · cooperative agreement · U01
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.
B. Kim Lee Sim · Sanaria · funded by National Institutes of Health
2021–2026 · cooperative agreement · U01
Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2021–2026 · cooperative agreement · U01
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.
B. Kim Lee Sim · Sanaria · funded by National Institutes of Health
2021–2026 · cooperative agreement · U01
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.
B. Kim Lee Sim · Sanaria · funded by National Institutes of Health
2021–2026 · cooperative agreement · U01
Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2021–2023 · research · R43
Attenuation of Liquid Formulation for PfSPZ Vaccine by X-Ray
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2021–2026 · cooperative agreement · U01
Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2021–2026 · cooperative agreement · U01
Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2021–2026 · cooperative agreement · U01
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.
B. Kim Lee Sim · Sanaria · funded by National Institutes of Health
2021–2024 · research · R43
Attenuation of Liquid Formulation for PfSPZ Vaccine by X-Ray
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2021–2027 · cooperative agreement · U01
Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2021–2027 · cooperative agreement · U01
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.
B. Kim Lee Sim · Sanaria · funded by National Institutes of Health
2020–2023 · research · R43
Enhancement of gametocytogenesis in Plasmodium falciparum by genetic engineering for improved PfSPZ Vaccine Manufacture
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2020–2026 · research · R44
A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage
B. Kim Lee Sim · Sanaria · funded by National Institutes of Health
2020–2023 · research · R43
A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage.
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2020–2022 · research · R43
A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage.
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2020–2022 · research · R43
Enhancement of gametocytogenesis in Plasmodium falciparum by genetic engineering for improved PfSPZ Vaccine Manufacture
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2020–2026 · research · R44
A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage
B. Kim Lee Sim · Sanaria · funded by National Institutes of Health
2020–2027 · research · R44
A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage
B. Kim Lee Sim · Sanaria · funded by National Institutes of Health
2019–2022 · research · R43
Genetically Modified Conditional Sexing A. stephensi Line for PfSPZ Manufacture
Peter F. Billingsley · Sanaria · funded by National Institutes of Health
2019–2021 · research · R43
Genetically Modified Conditional Sexing A. stephensi Line for PfSPZ Manufacture
Peter F. Billingsley · Sanaria · funded by National Institutes of Health
2018–2024 · research · R44
A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products
Peter F. Billingsley · Sanaria · funded by National Institutes of Health
2018–2020 · research · R43
A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products.
Peter F. Billingsley · Sanaria · funded by National Institutes of Health
2018–2021 · research · R43
A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products.
Peter F. Billingsley · Sanaria · funded by National Institutes of Health
2018–2025 · research · R44
A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products
Peter F. Billingsley · Sanaria · funded by National Institutes of Health
2018–2020 · research · R43
Development, GMP manufacture, and quality control release of a triple knock out genetically attenuated Plasmodium falciparum sporozoite vaccine
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2018–2021 · research · R43
Development, GMP manufacture, and quality control release of a triple knock out genetically attenuated Plasmodium falciparum sporozoite vaccine
Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health
2018–2024 · research · R44
A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products
Peter F. Billingsley · Sanaria · funded by National Institutes of Health
2017–2022 · research · R44
Immune Deficient Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture
Peter F. Billingsley · Sanaria · funded by National Institutes of Health